Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The chronobiology of migraine: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The chronobiology of migraine: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Migraine prevention with erenumab and migraine induction by calcitonin gene-related peptide (CGRP) both carry notable individual variance. We wanted to explore a possible association between individual efficacy of anti-CGRP treatment and susceptibility to migraine induction by CGRP.

METHODS: Thirteen migraine patients, previously enrolled in erenumab anti-CGRP receptor monoclonal antibody trials, received CGRP in a double-blind, placebo-controlled, randomized cross-over design to investigate their susceptibility to migraine induction. A standardized questionnaire was used to assess the efficacy of previous antibody treatment. The patients were stratified into groups of high responders and poor responders. Primary outcomes were incidence of migraine-like attacks and area under the curve of headache intensity after infusion of CGRP and placebo. All interviews and experiments were performed in laboratories at the Danish Headache Center, Copenhagen, Denmark.

RESULTS: Ten high responders and three poor responders were included. CGRP induced migraine-like attacks in ten (77%) patients, whereof two were poor responders, compared to none after placebo (p = 0.002). The area under the curve for headache intensity was greater after CGRP, compared to placebo, at 0-90 min (p = 0.009), and 2-12 h (p = 0.014). The median peak headache intensity score was 5 (5-9) after CGRP, compared to 2 (0-4) after placebo (p = 0.004).

CONCLUSIONS: Patients with an excellent effect of erenumab are highly susceptible to CGRP provocation. If an association is evident, CGRP provocation could prove a biomarker for predicting antibody treatment efficacy.

TRIAL REGISTRATION: Retrospectively registered at clinicaltrials.gov with identifier: NCT03481400 .

OriginalsprogEngelsk
TidsskriftThe Journal of Headache and Pain Online
Vol/bind19
Udgave nummer1
Sider (fra-til)105
ISSN1129-2377
DOI
StatusUdgivet - 2018

ID: 56668689